CA
PVLA

Corriente Advisors’s Palvella Therapeutics PVLA Stock Holding History

Corriente Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,375
Closed -$837K – 25
2020
Q2 		$837K Sell
3,375
-18,899
-85% -$4.42M 0.54% 15
2020
Q1 		$4.06M Buy
+22,274
New +$5.61M 4.39% 6

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Corriente Advisors's PVLA Position: Q3 2020 in Review

Corriente Advisors sold out of Palvella Therapeutics (PVLA) in Q3 2020, closing a stake of 3,375 shares — an estimated $837K sold.

Corriente Advisors first reported a position in PVLA in Q1 2020 and held it in 2 quarters. The position peaked at $4.06M in Q1 2020. 88 funds tracked by Wall St. Rank hold PVLA as of Q3 2020.

  • Corriente Advisors reported no remaining Palvella Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Corriente Advisors sold 3,375 Palvella Therapeutics shares in Q3 2020, an estimated $837K.
  • Corriente Advisors first reported a position in Palvella Therapeutics in Q1 2020 and held it in 2 quarters.
  • Corriente Advisors's Palvella Therapeutics position peaked at $4.06M in Q1 2020.
  • 88 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2020.

Based on Corriente Advisors's 13F filing for Q3 2020, filed 3 Nov 2020.